Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 5/20 | 0.56 |
| ▸ | TSHR | P16473 | 3/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 2/20 | 0.34 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.34 |
| ▸ | PDE3B | Q13370 | 3/20 | 0.34 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | SMYD3 | Q9H7B4 | 2/20 | 0.32 |
| ▸ | CECR2 | Q9BXF3 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3642063 | 1.00 | PARP1 (0.56) | PARP1TSHRTP53SMN1; SMN2BRD4 | |
| SCHEMBL3637630 | 1.00 | PARP1 (0.56) | PARP1TSHRTP53SMN1; SMN2BRD4 | |
| SCHEMBL5671423 | 0.81 | PARP1 (0.57) | PARP1TSHRTP53SMN1; SMN2BRD4 | |
| SCHEMBL16823814 | 0.80 | PARP1 (0.56) | PARP1TSHRTP53SMN1; SMN2BRD4 | |
| SCHEMBL20992169 | 0.80 | PARP1 (0.56) | PARP1TSHRTP53SMN1; SMN2BRD4 | |
| SCHEMBL17050354 | 0.80 | PARP1 (0.56) | PARP1TSHRTP53SMN1; SMN2BRD4 | |
| SCHEMBL18611861 | 0.79 | PARP1 (0.54) | PARP1TSHRTP53SMN1; SMN2BRD4 | |
| SCHEMBL19490441 | 0.78 | PARP1 (0.53) | PARP1TSHRTP53SMN1; SMN2BRD4 | |
| SCHEMBL17031847 | 0.78 | PARP1 (0.53) | PARP1TSHRTP53SMN1; SMN2BRD4 | |
| SCHEMBL7001533 | 0.75 | PARP1 (0.50) | PARP1TSHRSMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100016285-A1 | HETEROCYCLIDENE-N-(ARYL) ACETAMIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2010-01-21 | — | — | US | disclosed |
| EP-2128157-A1 | HETEROCYCLIDENE-N-(ARYL)ACETAMIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2009-12-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016285-A1 | HETEROCYCLIDENE-N-(ARYL) ACETAMIDE DERIVATIVE | CCNY, CCND3, NSD3 | PARP1 1468/4885TSHR 1731/4885TP53 3619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.